PCORI Continues to Come Under Scrutiny
Thursday, October 11, 2012
As policy makers continue to examine the best methods for controlling
the costs of health care, one of the lead supporters of comparative
effectiveness research (CER) is voicing concerns that the Patient
Centered Outcomes Research Institute (PCORI) is lacking the sense of
urgency to tackle high-impact clinical questions.
In an article published in Health Affairs, Harold Sox, who co-chaired
the 2009 Institute of Medicine panel on CER, argued that due to the
slow pace of clinical research, there are threats to PCORI being
reauthorized beyond the sunset date of September 2019 set by the
Affordable Care Act.
MDMA recently submitted comments with our members input on PCORI's
draft methodology that is intended to guide health care stakeholders
towards the best and most appropriate methods for conducting CER.
MDMA noted that PCORI should support research on wellness and
prevention to complement its current thinking on CER, pointing to the
growing trend of obesity in the U.S. as a key driver of health care
"If our country continues on this path, we can only begin to try to
speculate what the related costs will be for treating obesity related
conditions, such as diabetes, pulmonary hypertension and heart disease
in general," wrote MDMA.
MDMA continues our work with the Administration and Members of
Congress to improve the CER program and other parts of the health care
reform legislation that could harm innovation.